Multifocal Motor Neuropathy With Anti-GM1 Antibody: A Filipino Case Report


As far as we are aware of, we report the first documented case of a 51-year-old Filipino female with multifocal motor neuropathy who presented with asymmetric weakness, unusually in the lower extremity, and confirmed with anti-GM1 antibody.

The treatment of intravenous immunoglobulin with a total dose of 2 g/kg was initiated and repeated every two months with noticeable improvement based on electromyography and nerve conduction studies.

Apart from the unreported Filipino case of multifocal motor neuropathy substantiated by features in clinical, electrophysiologic, antibody testing and response to immunotherapy, the unique occurrence in a female and involving the lower extremity in this rare disorder deserve this present documentation. Multifocal motor neuropathy is seen more in males with a ratio of 2.7:1. It is described as a pure motor disease without sensory deficits and predominantly affects the upper extremities. The diagnosis for the disorder is supported by determination of ganglioside GM1 antibodies.

Keywords: multifocal motor neuropathy, case report

  1. Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1986 Sep 1;36(9):1260.
  2. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1991 Sep;30(3):397–401.
  3. Olney RK, Lewis RA, Putnam TD, Campellone Jr JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2003 Jan;27(1):117–21.
  4. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. The Lancet Neurology. 2005 May 1;4(5):309–19. 
  5. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. Journal of the Peripheral Nervous System. 2010 Dec;15(4):295–301. 
  6. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nature Reviews Neurology. 2012 Jan;8(1):48.
  7. Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatric Disease and Treatment. 2014;10:567. 
  8. Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews. 2015(3).
  9. Beadon K, Guimarães-Costa R, Léger JM. Multifocal motor neuropathy. Current Opinion in Neurology. 2018 Oct;31(5):559–64.
  10. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1988 Jul;24(1):73–8.
  11. Pestronk A, Chaudhry V, Feldman EL, Griffin JW, Cornblath DR, Denys EH, et al. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990 Mar;27(3):316–26. 
  12. Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy. Journal of the Peripheral Nervous System. 2019 Mar;24(1):64–71.

Articles related to the one you are viewing

There are currently no results to show, please try again later

CC BY: Open Access Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit